RECRUITING

Tau Networks in Psychotic Alzheimer's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.

Official Title

Tau Networks in Psychotic Alzheimer's Disease

Quick Facts

Study Start:2023-04-13
Study Completion:2029-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05847192

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Erica Christen, MS
CONTACT
516-562-3492
EChriste@northwell.edu
Michelle Gong, AS
CONTACT
516-562-3492
MGong@northwell.edu

Principal Investigator

Jeremy Koppel, MD
PRINCIPAL_INVESTIGATOR
Northwell Health

Study Locations (Sites)

The Feinstein Institutes for Medical Research
Manhasset, New York, 11030
United States

Collaborators and Investigators

Sponsor: Northwell Health

  • Jeremy Koppel, MD, PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-13
Study Completion Date2029-12-31

Study Record Updates

Study Start Date2023-04-13
Study Completion Date2029-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer Disease
  • Alzheimer Disease With Delusions
  • Alzheimer Disease With Psychosis